3,560 material Form 8-K filings that 2,489 companies we cover made with the SEC in October 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). 2,508 of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Supernus said the FDA recognized seven years of orphan-drug exclusive approval for ONAPGO (apomorphine HCl) for motor fluctuations in adults with advanced Parkinson's disease, with the exclusivity period starting on the February 3, 2025 approval date. The company also submitted a supplemental New Drug Application for a second supplier of ONAPGO and continues to expect potential FDA approval of that supplier by mid-year 2027. The filing gives no financial figures, but the exclusivity period is a regulatory protection for the product.
FDA recognized seven years of orphan-drug exclusive approval for ONAPGO, with the period starting February 3, 2025.
ONAPGO is described as the first and only subcutaneous apomorphine infusion device for motor fluctuations in adults with advanced Parkinson's disease.
Supernus submitted an sNDA for a second supplier of ONAPGO and expects potential FDA approval by mid-year 2027.
TruGolf said it believes it has regained compliance with Nasdaq's $2.5 million minimum stockholders' equity requirement. Nasdaq had flagged a shortfall based on stockholders' equity of $2,060,281 as of June 30, 2026, and the company credits the Polymath acquisition and a Series B preferred stock financing for the change. Nasdaq will keep monitoring compliance and may move to delist the stock if the company's next periodic report does not show compliance.
Nasdaq had cited stockholders' equity of $2,060,281 from the June 30, 2026 Form 10-Q, below the $2,500,000 minimum
Polymath Research acquisition, completed in October 2026, added Polymath's net assets to the balance sheet
Series B preferred financing: $2,950,000 aggregate exercise price for 3,278 shares, plus 3,000 additional Series B warrants
Nasdaq will monitor compliance and may delist if the next periodic report does not show compliance
Alaunos Therapeutics said it believes it has regained compliance with Nasdaq's $2.5 million stockholders' equity requirement, following the October 14, 2026 closing of a financing with aggregate gross proceeds of approximately $350.0 million. Nasdaq has not yet confirmed the company's determination, and a Nasdaq Hearings Panel hearing remains scheduled for November 10, 2026. The company's status could still be challenged if it does not evidence compliance when it files its 2026 annual report.
Nasdaq's April 9, 2026 deficiency letter cited stockholders' equity of $2,153,000 in the 2025 Form 10-K, below the $2,500,000 minimum.
The financing closed October 14, 2026, with approximately $350.0 million in gross proceeds before placement agent fees and other expenses.
A Fairmount Fund II waiver covers 6,268 Series C Preferred shares, valued at approximately $9.0 million, that would otherwise carry a cash settlement right.
The Panel hearing is set for November 10, 2026; the company expects it to be cancelled once Nasdaq confirms compliance, and Nasdaq will keep monitoring the requirement.
Valor Energy said it regained compliance with Nasdaq's $2.5 million minimum stockholders' equity requirement after raising its authorized common stock from 50 million to 500 million shares and reclassifying $41.90 million of warrants from liabilities to equity. The company also issued 4,510,000 warrants to investors on October 19, 2026. Nasdaq will keep monitoring, and the company may be delisted if it does not show compliance in its Form 10-Q for the period ended September 30, 2026.
Nasdaq notified the company on August 21, 2026 that its stockholders' deficit of $35,344,336 at June 30, 2026 did not meet the $2.5 million minimum
Authorized common stock was increased from 50,000,000 to 500,000,000 shares, effective August 6, 2026, and the June 2026 warrants were reclassified to equity
The company submitted a compliance plan to Nasdaq on October 5, 2026 and believes it has regained compliance
Failure to evidence compliance in the Form 10-Q for the period ended September 30, 2026 could lead to delisting
Nasdaq's Listing Qualifications staff said on October 20, 2026 that Vivos Therapeutics now meets the $2.5 million minimum stockholders' equity requirement, based on the company's October 19, 2026 8-K. The company said the SOD transaction, which included issuing Series C Convertible Preferred Stock, drove the improvement, but Nasdaq said the company could still face delisting if it does not show compliance in its next periodic report, and the preferred stock is convertible into up to 80,000,000 common shares, which could dilute existing holders.
Nasdaq letter dated October 20, 2026 says Vivos complies with the $2.5 million stockholders' equity minimum under Listing Rule 5550(b)(1).
Series C Convertible Preferred Stock with an aggregate stated value of $12,000,000 was issued as part of the SOD Sciences transaction, and is expected to increase stockholders' equity by more than $10 million.
Preferred stock converts at $0.15 per share into up to 80,000,000 common shares, subject to a 19.99% exchange cap pending stockholder approval.
Nasdaq said the company may be delisted if it does not evidence compliance upon filing its next periodic report.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.